Health BMS Pays $100M for Next-Gen Orum Therapeutics ADC for Blood Cancers January 17, 2024 53 TelecomJanuary 17, 2025[Updated] Vodafone Idea (Vi) 5G Service Reportedly Rolled Out in India TelecomJanuary 17, 2025JioFiber, Jio AirFiber Subscribers Get Two-Year YouTube Premium Access on Select Plans TelecomJanuary 17, 2025TRAI Mandates Telecom Operators to Offer Specialised Voice and SMS Packs, Benefitting Consumers in Rural Areas TelecomJanuary 17, 2025Airtel Plans to Refarm 4G Spectrum to Boost 5G Coverage in Rural B & C Circles: Report TelecomJanuary 11, 2025Airtel Wi-Fi Plans Starting From Rs. 699 Now Bundles Free Zee5 OTT Subscription Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs. Prime Plus Facebook Twitter Pinterest WhatsApp SportsJanuary 6, 2025ICC World Test Championship points table 2023-25 after South Africa vs Pakistan 2nd Test Sports BGMI ESL SPS Challenge Season Week 3: Teams, Schedule, And More January 6, 2025 Sports Free Fire Max Redeem Codes Today January 7 brings cool rewards January 6, 2025 Sports “Shubman Gill is highly overrated, surviving because he gets ten chances”: Ex-India chief selector’s scathing take January 6, 2025
